[EN] BENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSITIONS DE BENZIMIDAZOLE
申请人:WYETH CORP
公开号:WO2009086138A1
公开(公告)日:2009-07-09
This invention relates generally to benzimidazole-based modulators of Liver X receptors (LXRs) and related methods (Formula I). wherein R2 is C6-C10 aryl or heteroaryl including 5-10 atoms, each of which is: (i) substituted with 1 R7, and (ii) optionally substituted with from 1-5 Re; and R1, R3, R4, R5, R6, R7, and Re are defined herein.
This invention relates generally to benzimidazole-based modulators of Liver X receptors (LXRs) having formula (I) and related methods:
wherein R
2
is C
6
-C
10
aryl or heteroaryl including 5-10 atoms, each of which is: (i) substituted with 1 R
7
, and (ii) optionally substituted with from 1-5 R
e
; and R
1
, R
3
, R
4
, R
5
, R
6
, R
7
, and R
e
are defined herein.
1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists
作者:Jeremy M. Travins、Ronald C. Bernotas、David H. Kaufman、Elaine Quinet、Ponnal Nambi、Irene Feingold、Christine Huselton、Anna Wilhelmsson、Annika Goos-Nilsson、Jay Wrobel
DOI:10.1016/j.bmcl.2009.11.099
日期:2010.1
A series of 1-(3-aryloxyaryl)benzimidazoles incorporating a sulfone substituent (6) was prepared. High affinity LXR ligands were identified (LXRβ binding IC50 values <10 nM), some with excellent agonist potency and efficacy in a functional assay of LXR activity measuring ABCA1 mRNA increases in human macrophage THP1 cells. The compounds were typically stable in liver microsome preparations and had